AwardTape · Defense awards · Research and development · Health R&D · HT942525CE039
HT942525CE039: $3.2M definitive contract to Inhalon Biopharma, Inc
Inhalon Biopharma, Inc holds a definitive contract from Defense Health Agency with $3.2M obligated since Oct 2023, against a ceiling of $3.2M. Latest action Sep 22, 2025.
A phase 1 placebo-controlled dose-escalation safety and pharmacokinetic study of in-007, a nebulized, pan-sars ace2-decoy therapeutic for pandemic preparedness
| PIID | HT942525CE039 |
|---|---|
| Type | definitive contract |
| Company | Inhalon Biopharma, Inc |
| Agency | Defense Health Agency |
| Contracting office | ARMY MED RES ACQ ACTIVITY |
| Category | Research and development · Health R&D |
| PSC | AN13 HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| NAICS | 541715 RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) |
| Obligated since Oct 2023 | $3.2M |
| Total obligated (lifetime) | $3.2M |
| Ceiling (base and all options) | $3.2M |
| Base date | Sep 22, 2025 |
| Latest action | Sep 22, 2025 |
| End date | Dec 31, 2027 |
| Actions since Oct 2023 | 1 |
| Pricing | Fixed price level of effort |
| Competition | Full and open competition |
| Place of performance | NC |
| Source | USAspending.gov record |
| Reporting lag | DoD 90 days |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Place of performance shows the state only.
Terminal: alerts on new orders and modifications to this contract, and CSV export.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial